NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Ibalizumab

Last Revision: January 18, 2021.

Estimated reading time: 1 minute

CASRN: 680188-33-4

Drug Levels and Effects

Summary of Use during Lactation

No published information is available on the use of ibilizumab during breastfeeding. Because ibilizumab is a large protein molecule with a molecular weight of 150,000 Da, the amount in milk is likely to be very low and absorption by the infant is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, ibilizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Ibilizumab is a human immunoglobulin G4 (IgG4) antibody. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G by up to 79%.[1,2] A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%. Specific IgG subclasses decreased by different amounts, with Holder pasteurization having little effect on IgG4 activity.[3] None of the studies measured IgG activity.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Adhisivam B, Vishnu Bhat B, Rao K, et al. Effect of Holder pasteurization on macronutrients and immunoglobulin profile of pooled donor human milk. J Matern Fetal Neonatal Med. 2019;32:3016–9. [PubMed: 29587541]
2.
Koenig A, de Albuquerque Diniz EM, Barbosa SF, et al. Immunologic factors in human milk: The effects of gestational age and pasteurization. J Hum Lact. 2005;21:439–43. [PubMed: 16280560]
3.
Rodríguez-Camejo C, Puyol A, Fazio L, et al. Antibody profile of colostrum and the effect of processing in human milk banks: Implications in immunoregulatory properties. J Hum Lact. 2018;34:137–47. [PubMed: 28586632]

Substance Identification

Substance Name

Ibalizumab

CAS Registry Number

680188-33-4

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal

Antibodies, Antiviral

Anti-HIV Agents

Antiviral Agents

Anti-Retroviral Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Dupilumab[Drugs and Lactation Database (...]
    Review Dupilumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Cemiplimab[Drugs and Lactation Database (...]
    Review Cemiplimab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Brodalumab[Drugs and Lactation Database (...]
    Review Brodalumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Galcanezumab[Drugs and Lactation Database (...]
    Review Galcanezumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Evolocumab[Drugs and Lactation Database (...]
    Review Evolocumab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...